Cargando…

Liver-directed lentiviral gene therapy corrects hemophilia A mice and achieves normal-range factor VIII activity in non-human primates

Liver gene therapy with adeno-associated viral (AAV) vectors delivering clotting factor transgenes into hepatocytes has shown multiyear therapeutic benefit in adults with hemophilia. However, the mostly episomal nature of AAV vectors challenges their application to young pediatric patients. We devel...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milani, Michela, Canepari, Cesare, Liu, Tongyao, Biffi, Mauro, Russo, Fabio, Plati, Tiziana, Curto, Rosalia, Patarroyo-White, Susannah, Drager, Douglas, Visigalli, Ilaria, Brombin, Chiara, Albertini, Paola, Follenzi, Antonia, Ayuso, Eduard, Mueller, Christian, Annoni, Andrea, Naldini, Luigi, Cantore, Alessio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068791/ https://www.ncbi.nlm.nih.gov/pubmed/35508619 http://dx.doi.org/10.1038/s41467-022-30102-3

Ejemplares similares

Recombinant factor VIII Fc (rFVIIIFc) fusion protein reduces immunogenicity and induces tolerance in hemophilia A mice
por: Krishnamoorthy, Sriram, et al.
Publicado: (2015)

Modulation of immune responses in lentiviral vector-mediated gene transfer
por: Annoni, Andrea, et al.
Publicado: (2019)

Genome editing for scalable production of alloantigen‐free lentiviral vectors for in vivo gene therapy
por: Milani, Michela, et al.
Publicado: (2017)

Hemophilia A gene therapy via intraosseous delivery of factor VIII-lentiviral vectors
por: Miao, Carol H.
Publicado: (2016)

Transduction of modified factor VIII gene improves lentiviral gene therapy efficacy for hemophilia A
por: Gong, Jie, et al.
Publicado: (2021)

WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
por: Cantore, Alessio, et al.
Publicado: (2020)

FcRn Rescues Recombinant Factor VIII Fc Fusion Protein from a VWF Independent FVIII Clearance Pathway in Mouse Hepatocytes
por: van der Flier, Arjan, et al.
Publicado: (2015)

CD14(+)/CD31(+) monocytes expanded by UM171 correct hemophilia A in zebrafish upon lentiviral gene transfer of factor VIII
por: Elnaggar, Muhammad, et al.
Publicado: (2022)

Laboratory-Scale Lentiviral Vector Production and Purification for Enhanced Ex Vivo and In Vivo Genetic Engineering
por: Soldi, Monica, et al.
Publicado: (2020)

Generation of an Optimized Lentiviral Vector Encoding a High-Expression Factor VIII Transgene for Gene Therapy of Hemophilia A
por: Johnston, Jennifer M., et al.
Publicado: (2012)

Improved intravenous lentiviral gene therapy based on endothelial-specific promoter-driven factor VIII expression for hemophilia A
por: Gong, Jie, et al.
Publicado: (2023)

Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice
por: Annoni, Andrea, et al.
Publicado: (2013)

Efficient and safe correction of hemophilia A by lentiviral vector-transduced BOECs in an implantable device
por: Olgasi, Cristina, et al.
Publicado: (2021)

Transcriptional Targeting and MicroRNA Regulation of Lentiviral Vectors
por: Merlin, Simone, et al.
Publicado: (2019)

Escape or Fight: Inhibitors in Hemophilia A
por: Merlin, Simone, et al.
Publicado: (2020)

Interferon gene therapy reprograms the leukemia microenvironment inducing protective immunity to multiple tumor antigens
por: Escobar, Giulia, et al.
Publicado: (2018)

Postpartum Acquired Hemophilia Factor VIII Inhibitors and Response to Therapy
por: Karakuş, Volkan, et al.
Publicado: (2012)

Idiopathic Acquired Hemophilia A with Undetectable Factor VIII Inhibitor
por: Abt, Nicholas B., et al.
Publicado: (2014)

The factor VIII treatment history of non‐severe hemophilia A
por: Abdi, Amal, et al.
Publicado: (2020)

Delivery of Factor VIII Gene into Skeletal Muscle Cells Using Lentiviral Vector
por: Jeon, Hyun Jeong, et al.
Publicado: (2010)

Design of a regulated lentiviral vector for hematopoietic stem cell gene therapy of globoid cell leukodystrophy
por: Ungari, Silvia, et al.
Publicado: (2015)

Innovative Approaches for Immune Tolerance to Factor VIII in the Treatment of Hemophilia A
por: Sherman, Alexandra, et al.
Publicado: (2017)

Hemophilia and von Willebrand disease: Factor VIII and von Willebrand factor
por: Sharma, Prashant
Publicado: (2019)

Factor VIII: Perspectives on Immunogenicity and Tolerogenic Strategies for Hemophilia A Patients
por: Khalilian, Sheyda, et al.
Publicado: (2020)

A Single Chain Variant of Factor VIII Fc Fusion Protein Retains Normal In Vivo Efficacy but Exhibits Altered In Vitro Activity
por: Buyue, Yang, et al.
Publicado: (2014)

Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice
por: Joo, Julia H., et al.
Publicado: (2022)

Recombinant factor VIII in the management of hemophilia A: current use and future promise
por: Powell, Jerry S
Publicado: (2009)

Characterization of anti-factor VIII antibody in a patient with acquired hemophilia A
por: Oh, Jisu, et al.
Publicado: (2013)

Potential role of a new PEGylated recombinant factor VIII for hemophilia A
por: Wynn, Tung Thanh, et al.
Publicado: (2016)

Clot stability as a determinant of effective factor VIII replacement in hemophilia A
por: Leong, Lilley, et al.
Publicado: (2017)

Many factor VIII products available in the treatment of hemophilia A: an embarrassment of riches?
por: Lieuw, Kenneth
Publicado: (2017)

Factor VIII Intron 22 Inversion in Severe Hemophilia A Patients in Palestine
por: Mahmoud Abu Arra, Caesar, et al.
Publicado: (2020)

Treatment of Hemophilia A Using Factor VIII Messenger RNA Lipid Nanoparticles
por: Chen, Chun-Yu, et al.
Publicado: (2020)

Factor VIII and Factor IX Activity Measurements for Hemophilia Diagnosis and Related Treatments
por: Bowyer, Annette E., et al.
Publicado: (2022)

Association between Sports Participation, Factor VIII Levels and Bleeding in Hemophilia A
por: Bukkems, Laura H., et al.
Publicado: (2022)

The prevalence of factor VIII and IX inhibitors among Saudi patients with hemophilia: Results from the Saudi national hemophilia screening program
por: Owaidah, Tarek, et al.
Publicado: (2017)

Novel Severe Hemophilia A Mouse Model with Factor VIII Intron 22 Inversion
por: Han, Jeong Pil, et al.
Publicado: (2021)

B cell–activating factor modulates the factor VIII immune response in hemophilia A
por: Doshi, Bhavya S., et al.
Publicado: (2021)

Bispecific antibodies mimicking factor VIII in hemophilia A: converting innovation to an essential medicine
por: Hermans, Cedric, et al.
Publicado: (2023)

Factor VIII inhibitors in hemophilia A treated with emicizumab: longitudinal follow-up of outcomes
por: Levy-Mendelovich, Sarina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_s99jfhp9d6ih01l8138cv8o2sf